The CATT Research Group April 2011 In 2005, clinical trials established the efficacy of ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use [Read More]
Category: Research and Developments
A Primer on the Use of Stem Cells in Ophthalmology
Irving J. Arons September 2, 2010 (Version 3, Updated September 14, 2010) I recently came across an interesting news release from International Stem Cell Corporation (ISCO) announcing that it had formed a new business unit, Cytovis, to focus on stem cell programs in ophthalmology, including CytoCor for the cornea and CytoRet for the retina. That [Read More]
Genetic testing sheds light on degenerative eye disease
Press Release February 13, 2007 Updated 5/16/2010 ANN ARBOR, Mich. — Genetic testing for eye disease is providing vital information about complex retinal diseases, especially when used to confirm a clinician’s diagnosis. In a newly published review of such tests that were conducted over a five-year period at the University of Michigan Kellogg Eye Center, [Read More]
Study Shows Lucentis and Avastin to be Equal
by Dan Roberts February 3, 2010 Investigators at Kaiser Permanente Southern California in Pasadena reported in the February 2010 issue of Ophthalmology that Avastin and Lucentis performed equally in recent testing. In an indirect comparison of the two drugs, study author Dr. Donald Fong and coauthors reviewed the records of 452 patients treated for wet [Read More]
PEG-POD – New Gene Delivery Tool
by Dan Roberts January 2010 Researchers have developed a new tool for gene therapy that significantly increases gene delivery to cells in the retina compared to other carriers and DNA alone. The study was published in the January 2010 issue of The Journal of Gene Medicine by Tufts University School of Medicine and the Sackler [Read More]